An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Fulvestrant (Primary) ; Fulvestrant (Primary)
- Indications Early breast cancer
- Focus Adverse reactions
- Sponsors Atossa Genetics
- 12 Apr 2018 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
- 12 Apr 2018 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
- 09 May 2017 According to an Atossa Genetics media release, the Institutional Review Board associated with Montefiore Medical Center (Biomedical Research Alliance of New York IRB) has approved this Phase 2 study that was recently transferred to Montefiore.